Greenfield-based Elanco U.S. Inc. has announced an agreement to add the companion animal vaccine portfolio of one of its competitors. The $885 million deal with Boehringer Ingelheim Vetmedica Inc. involves dozens of cat, dog and rabies vaccines, as well as an Iowa manufacturing facility. Shawn McKee, Elanco’s Senior Director of Companion Animal U.S. explains what the planned acquisition will mean for the company. 

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}